{
  "first_published_at": "2008-06-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON085019", 
  "title": "Nicorandil: gastrointestinal ulceration", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\", \"gi-hepatology-pancreatic-disorders\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\", \"GI, hepatology and pancreatic disorders\"]}", 
  "_document_number": 289, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology", 
    "gi-hepatology-pancreatic-disorders"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Nicorandil: gastrointestinal ulceration</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: June 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Nicorandil is associated with a risk of gastrointestinal ulceration, including perianal ulceration. Healthcare professionals should consider nicorandil treatment as a possible cause in patients who present with symptoms of gastrointestinal-tract ulceration<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Nicorandil (Ikorel) is widely prescribed for the prevention and treatment of angina. Recommended initial dose is 10 mg twice a day, although 5 mg twice a day can be given (particularly for those who are susceptible to headache). This dose should be titrated up, depending on clinical response: usual dose is 10&ndash;20 mg twice a day; up to 30 mg twice a day may be used if necessary.</p><p>Although mouth ulceration has long been recognised as a side-effect of nicorandil treatment, its use has more recently been associated with ulceration of any region of the gastrointestinal tract including the perianal area. The ulceration is commonly severe and, in a few patients, has led to perforation. Time to onset may vary widely.</p><p>Ulcers that result from nicorandil are refractory to treatment, including surgery; they respond only to withdrawal of nicorandil. However, nicorandil is frequently overlooked as a potential cause for such ulcers, <cite>Baker RP, et al. Tech Coloprotocol 2007; 11: 343-45</cite>and patients may therefore undergo unnecessary and unsuccessful procedures before the cause is recognised.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>GPs and other healthcare professionals should consider nicorandil treatment as a possible cause in patients who present with symptoms of gastrointestinal ulceration</li>\r\n\t\t\t\t<li>Ulcers that result from nicorandil are refractory to treatment; they respond only to withdrawal of nicorandil</li>\r\n\t\t\t\t<li>Nicorandil withdrawal should take place only under the supervision of a cardiologist</li>\r\n\t\t\t</ul></div><p>&nbsp;</p><p><em>Article citation: Drug Safety Update June 2008; Vol 1, Issue 11: 5</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Nicorandil (Ikorel) is widely prescribed for the prevention and treatment of angina. Recommended initial dose is 10 mg twice a day, although 5 mg twice a day can be given (particularly for those who are susceptible to headache). This dose should be titrated up, depending on clinical response: usual dose is 10&#8211;20 mg twice a day; up to 30 mg twice a day may be used if necessary.</p><p>Although mouth ulceration has long been recognised as a side-effect of nicorandil treatment, its use has more recently been associated with ulceration of any region of the gastrointestinal tract including the perianal area. The ulceration is commonly severe and, in a few patients, has led to perforation. Time to onset may vary widely.</p><p>Ulcers that result from nicorandil are refractory to treatment, including surgery; they respond only to withdrawal of nicorandil. However, nicorandil is frequently overlooked as a potential cause for such ulcers, <cite>Baker RP, et al. Tech Coloprotocol 2007; 11: 343-45</cite>and patients may therefore undergo unnecessary and unsuccessful procedures before the cause is recognised.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>GPs and other healthcare professionals should consider nicorandil treatment as a possible cause in patients who present with symptoms of gastrointestinal ulceration</li>\r\n\t\t\t\t<li>Ulcers that result from nicorandil are refractory to treatment; they respond only to withdrawal of nicorandil</li>\r\n\t\t\t\t<li>Nicorandil withdrawal should take place only under the supervision of a cardiologist</li>\r\n\t\t\t</ul></div><p>&#160;</p><p><em>Article citation: Drug Safety Update June 2008; Vol 1, Issue 11: 5</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-06-01", 
  "date_last_modified": "2010-09-21", 
  "_assets": [], 
  "_item_id": 289, 
  "summary": "Nicorandil is associated with a risk of gastrointestinal ulceration, including perianal ulceration. Healthcare professionals should consider nicorandil treatment as a possible cause in patients who present with symptoms of gastrointestinal-tract ulceration", 
  "body": "Article date: June 2008\n\nNicorandil (Ikorel) is widely prescribed for the prevention and treatment of angina. Recommended initial dose is 10 mg twice a day, although 5 mg twice a day can be given (particularly for those who are susceptible to headache). This dose should be titrated up, depending on clinical response: usual dose is 10–20 mg twice a day; up to 30 mg twice a day may be used if necessary.\n\nAlthough mouth ulceration has long been recognised as a side-effect of nicorandil treatment, its use has more recently been associated with ulceration of any region of the gastrointestinal tract including the perianal area. The ulceration is commonly severe and, in a few patients, has led to perforation. Time to onset may vary widely.\n\nUlcers that result from nicorandil are refractory to treatment, including surgery; they respond only to withdrawal of nicorandil. However, nicorandil is frequently overlooked as a potential cause for such ulcers, [^1]and patients may therefore undergo unnecessary and unsuccessful procedures before the cause is recognised. \n\nAdvice for healthcare professionals:  \n  \n  * GPs and other healthcare professionals should consider nicorandil treatment as a possible cause in patients who present with symptoms of gastrointestinal ulceration  \n  * Ulcers that result from nicorandil are refractory to treatment; they respond only to withdrawal of nicorandil  \n  * Nicorandil withdrawal should take place only under the supervision of a cardiologist  \n  \n \n\nArticle citation: Drug Safety Update June 2008; Vol 1, Issue 11: 5\n\n[^1]: Baker RP, et al. Tech Coloprotocol 2007; 11: 343-45\n"
}